Can a common spice tame Asthma's airway inflammation?

NCT ID NCT07792395

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This phase 2 trial tests whether daily ginger extract capsules can improve airway responsiveness and reduce inflammation in adults with asthma. Participants with mild to severe persistent asthma, despite using inhaled corticosteroids, will receive either ginger extract or a placebo for a set period. Researchers will measure changes in lung function, markers of inflammation, and asthma symptoms. The goal is to see if ginger could serve as a useful add-on to standard asthma care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ginger extract taken as a daily capsule
What this could lead to
If ginger extract improves airway responsiveness and reduces inflammation, it could become a complementary add-on treatment for people with asthma.
What could go wrong
This is a small early-phase trial with only 32 participants, so results may not apply broadly. Ginger may also cause digestive upset or interact with other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 years or older with mild to severe persistent asthma as defined by NIH National Asthma Education and Prevention Program (NAEPP) guidelines, with asthma that is not optimally controlled despite current use of inhaled corticosteroids with or without inhaled long-acting beta agonists. 2. Treatment with inhaled corticosteroids (ICS), with or without long-acting beta-agonists/long-acting muscarinic antagonists and montelukast. 3. Physician-diagnosed asthma confirmed by history/report, pulmonary function testing with FEV1 ≥60% predicted or ≥1.5 L, and methacholine testing with baseline methacholine PD20 \<16 mg/mL if taking ICS or \<8 mg/mL if not taking ICS at Visit 2. 4. Non-smoker of tobacco, e-cigarettes, or marijuana for ≥1 year. Nicotine patch or gum is permitted. 5. Smoking history of ≤10 pack-years. 6. Suboptimal asthma control as determined by an Asthma Control Test (ACT) score ≤19 at the Screening and Randomization Visits. 7. Ability to understand English or Spanish, understand the study procedures, and comply with them f r the entire study period. 8. Participants of childbearing potential must have negative urine pregnancy testing as required by the protocol and agree to use effective contraception during the trial. Exclusion Criteria: 1. Major chronic illness that, in the judgment of the study physician, would interfere with study participation, including non-skin cancer, uncontrolled diabetes mellitus, coronary artery disease, congestive heart failure, stroke, severe hypertension, renal failure, liver disorders, malabsorption disorders, immunodeficiency states, major neuropsychiatric disorders, or seizure disorders. 2. Cardiovascular conditions including myocardial infarction or stroke within the previous 3 months, uncontrolled hypertension, or known aortic aneurysm. 3. History of physician-diagnosed chronic bronchitis, emphysema, or COPD. 4. Current use of ginger supplements. 5. Oral corticosteroid use within the previous 6 weeks. 6. Use of an investigational treatment within the previous 30 days. 7. Use of anticoagulants, such as warfarin, rivaroxaban, or similar agents. 8. Known adverse reaction to ginger or ginger products. 9. Cancer other than skin cancer. 10. Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. 11. Inability or unwillingness to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Columbia University Asthma Center

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.